To amend the Public Health Service Act with respect to the Living Organ Donation Reimbursement Program.

The 'Expanding Support for Living Donors Act of 2026' (HR7868) was introduced in the House of Representatives on March 9, 2026, by Rep. DelBene (D-WA) with two cosponsors. The bill has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means. This indicates an early stage in the legislative process, requiring committee consideration before any further action. The bill amends the Public Health Service Act to expand the Living Organ Donation Reimbursement Program. Specifically, it prohibits limiting eligibility for reimbursement based on household income if the income is at or below 700 percent of the poverty line. Crucially, it sets the maximum permissible reimbursement amount for qualifying expenses at $10,000 for fiscal year 2027, with subsequent adjustments based on the Consumer Price Index. This bill authorizes an increase in financial incentives for living organ donors, but it does not appropriate specific funds; actual funding would depend on subsequent appropriations. The mechanism of increasing financial incentives for living organ donation is intended to boost the supply of organs. A higher supply of organs directly translates to an increased number of transplant procedures. This would create a structural increase in demand for diagnostic services (for donor screening, recipient matching, and post-transplant monitoring), medical devices used in transplant surgeries, and post-operative care, including pharmaceuticals. Companies providing these services and products are positioned to benefit. For example, diagnostic companies like Labcorp ($LH) and Quest Diagnostics ($DGX) would see increased testing volumes. Medical device companies such as Medtronic ($MDT) and Stryker ($SYK) would experience higher demand for their surgical and post-operative products. Diversified healthcare companies like Johnson & Johnson could see increased demand for relevant pharmaceutical and medical device segments. Looking at recent market data, the healthcare sector has shown mixed performance. Labcorp ($LH) is currently at $259.46, down 4.83% over the last 7 days and 1.8% over 30 days. Quest Diagnostics ($DGX) is at $194.87, down 4.48% over 7 days and 0.33% over 30 days. Medtronic ($MDT) is at $81.47, down 2.1% over 7 days and 6.51% over 30 days. Stryker ($SYK) is at $320.66, down 2.64% over 7 days and 2.07% over 30 days. Johnson & Johnson is at $227.56, up 0.64% over 7 days but down 5.36% over 30 days. Teladoc Health ($TDOC), a telehealth provider, is at $5.97, up 0.84% over 7 days and 16.15% over 30 days, but its direct relevance to organ transplantation is limited. The recent Presidential Memorandum on Accelerating Medical Treatments for Serious Mental Illness and the Presidential Determination on Large-Scale Energy and Energy-Related Infrastructure are not directly relevant to this bill, as they target different sectors and policy areas. As of today, April 28, 2026, the bill is in its early stages, having only been referred to committee. Significant legislative steps, including committee hearings, markups, potential floor votes in the House, and then the entire Senate process, would need to occur for the bill to advance. The bipartisan sponsorship (Democrat lead, with two cosponsors including one Republican) suggests some potential for broader support, but passage is not guaranteed.